Neurology Minute Podcast

Vamorolone shows similar reported motor improvement to traditional corticosteroids in Duchenne muscular dystrophy, with better height Z-scores suggesting less growth suppression. Cross-trial comparisons, differing cohorts and uncertain long-term significance prevent a claim of clinical superiority.

Infantile epilepsy should not be managed as a single disorder defined only by seizure frequency. Identifying the cause and classifying the electroclinical syndrome guide treatment; about two-thirds have epilepsy treatable with medication alone, while persistent seizures should prompt early consideration of specialised diets, surgery or other therapies.

Family history, an overall polygenic risk score and individual migraine-associated variants produce different findings after paediatric concussion. Family history is associated in two of five models, the overall score is not associated, and four of 40 variants are linked to increasing headache severity, supporting cautious interpretation rather than prediction.

A 4.5-point fall in Myasthenia Gravis Activities of Daily Living score with cemdisiran monotherapy is a within-group change; the placebo-adjusted effect is 2.3 points and meets the stated threshold for clinical meaning. The trial also challenges assumptions that combination C5 targeting must outperform monotherapy and keeps mechanism and safety interpretation proportionate.

Negative myoclonus is a brief loss of tonic muscle activity rather than an added jerk or tremor. Recognising asterixis, dropped objects, writing difficulty, head nodding or falls helps direct assessment towards epileptic cortical events, metabolic disturbance, medicine effects or structural neurological disease.

A promising biological rationale and numerical treatment signal do not overcome a trial that misses its primary endpoint. Troriluzole for spinocerebellar ataxia illustrates how slower-than-expected placebo progression, externally controlled follow-up data and residual bias can leave clinicians counselling patients honestly about benefit and regulatory uncertainty.

An open-label phase followed by randomised withdrawal helps test whether improvement in neurogenic orthostatic hypotension depends on continued treatment. Symptom worsening after ampreloxetine withdrawal in the pre-planned multiple system atrophy subgroup supports a mechanism-based signal, while still requiring cautious interpretation alongside standing blood pressure and functional impact.

Identical levodopa doses do not necessarily produce identical exposure. In a small prospective cohort, women had higher total exposure and peak concentrations, with more wearing off and dyskinesia; the finding supports careful review of response timing and motor complications without establishing fixed sex-based dosing rules.

A positive depression or anxiety screen in epilepsy starts a clinical conversation rather than completing the assessment. Direct symptom review, anti-seizure medication review, safe antidepressant selection, immediate escalation of active suicidality and psychiatry referral after two unsuccessful selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor trials define the management pathway.

Neurology and critical-appraisal teams get a focused update on fenebrutinib in early relapsing multiple sclerosis. The FENhance trials link substantial reductions in relapse rate and MRI lesion activity with less definitive individual disability outcomes, while mortality imbalance, infection-related serious events and liver enzyme elevation remain important safety considerations.